Combining PD-1 Monoclonal Antibody and HDAC Inhibitor with Conventional P-Gemox Significantly Improves the Treatment Outcome for NK/T Cell Lymphoma
From June 17th to 23rd, 2023, the 17th International Conference on Malignant Lymphoma (ICML) was held grandly in Lugano, Switzerland. As the world's largest conference on malignant lymphoma, ICML has become an essential event in the field of lymphoma research and treatment over the past decades, aiming to present and discuss the latest basic, translational, and clinical research on lymphoma. NK/T cell lymphoma is a relatively rare hematological malignancy with no standardized treatment regimen. At this conference, Dr. Huiqiang Huang from the Cancer Center of Sun Yat-sen University,China, gave an enlightening lecture on the treatment strategy for NK/T cell lymphoma. Oncology Frontier has specially interviewed Professor Huang and compiled the contents as follows: